跳至主要内容
临床试验/NCT06256887
NCT06256887Enrolling By Invitation不适用

SONNO - Sleep Spindles Organization as an Early Neural Marker of Neuromotor Outcome: a New, Fast, Safe, Cost-effective and Infant-friendly EEG Tool to Monitor Early Sensory-motor Function in Infants at Risk of Neuromotor Disorders.

IRCCS Fondazione Stella Maris3 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2023年11月30日最近更新:
适应症

试验速览

阶段
不适用
状态
Enrolling By Invitation
入组人数
80
试验地点
3
主要终点
Sleep EEG (T1,T2) - quantitative sleep spindles analysis

研究概览

简要总结

The goal of this observational study is to test the effectiveness of quantitative early biomarkers in the sleep electroencephalogram (EEG), namely sleep spindles, as predictors of early sensorimotor maturation and long-term motor outcome. Spindles are discrete events, prominent over sensorimotor areas, that reflect motor learning overnight consolidation. They represent a potential marker for the investigation of altered early sensorimotor reorganization and long-term motor outcomes in the case of neuromotor pathologies. To test this hypothesis, we will validate the prognostic accuracy of a semi-automated EEG sleep-spindles analysis in two clinical populations: 1) infants with a perinatal brain lesion, at risk of Cerebral Palsy (CP), 2) infants with Spinal muscular atrophy type 1 (SMA1), a neuromuscular disease detectable at birth with variable response to early pharmacological treatment. A group of typically developing infants (at very low neurological risk) will be enrolled in the study as control group. All participants will undergo two sleep EEG recordings at 2-5 months (T1) and 12 months (T2), respectively. Short-term neuromotor outcome will be evaluated at T1 and T2, through standard and validated assessment. Long-term neuromotor development will be defined at 18 months (T3; i.e. CP vs NO CP; SMA treatment responders vs No responders). Primary clinical and motor outcomes will be used for estimating the effectiveness of spindles' features at T1 and T2 as predictors of later clinical and motor outcomes at T3. EEG sleep features will be considered both cross-sectionally, at each time point (T1, and T2), and from a longitudinal perspective. Differences in the EEG sleep-spindle features will be evaluated within- and between-groups.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
2 Months 至 5 Months(Child)
性别
All
接受健康志愿者

入选标准

  • Infants aged 0-5 months who are at high-risk of Cerebral Palsy (CP): preterm and at term infants with a documented pre- or perinatal brain lesion at the neonatal brain MRI (i.e. hypoxic-ischemic brain injury, ischemic or hemorrhagic stroke, cystic periventricular leukomalacia, periventricular hemorrhagic infarction associated with germinal matrix-intraventricular haemorrhage);
  • Infant aged 0-5 months who have received the diagnosis of SMA1, according to the perinatal genetic screening, and undergo early pharmacological treatment;
  • Infants aged 0-5 months at very low neurodevelopmental risk (Control group): infants born preterm or at term in absence of perinatal neurological complications.
  • Exclusion Criteria (apply all groups):
  • Presence of drug-resistant epilepsy or active epilepsy at T1,
  • Severe sensory deficits (blindness or deafness)
  • Diagnosis of progressive neurological disorders, other than SMA.

排除标准

  • 未提供

结局指标

主要结局

Sleep EEG (T1,T2) - quantitative sleep spindles analysis

时间窗: 2-5 months, 12 (+/- 1) months

Primary predictive measure of the study

Clinical dichotomous outcome

时间窗: 18 (+/- 3) months

For infants with perinatal brain damage, the primary outcome will be the diagnosis of CP: CP-YES vs CP-NO. For infants with SMA, the primary outcome will be the response to treatment: responders (SMA-R) vs non-responders (SMA-NR).

次要结局

  • General Movements Assessment (GMA; T1)(2-5 months)
  • Peabody Developmental Motor Scale (PDMS-II; T2 and T3)(12 (+/- 1) months, 18 (+/- 3) months)
  • Hammersmith Infant Neurological Examination (HINE; T1, T2 and T3)(2-5 months, 12 (+/- 1) months, 18 (+/- 3) months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Viviana Marchi

MD, PhD

IRCCS Fondazione Stella Maris

研究点 (3)

Loading locations...

相似试验